57- Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial
of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch
Ophthalmol. 2005;123:903–12. - Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm
Bowel Dis. 1998;4:142–8. - Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab
for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled
trial. Gut. 2006;55:505–9. - Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment
of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol.
2003;98:1821–6. - Arguelles-Arias F, Castro-Laria L, Lobaton T, Aguas-Peris M, Rojas-Feria M, Barreiro-de
Acosta M, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory
bowel disease. Dig Dis Sci. 2013;58:2949–54. - Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recal-
citrant pyoderma gangrenosum. J Burns Wounds. 2006;5:e8. - Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gan-
grenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid
arthritis. Clin Rheumatol. 2007;26:2205–6. - Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments:
a way to treat and trigger? Acta Derm Venereol. 2010;90:183–5. - Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory
chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol
Venereol. 2007;21:408–10. - Rosen T, Martinelli P. Erythema nodosum associated with infliximab therapy. Dermatol Online
J. 2008;14:3. - Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, et al. A double-
blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis.
J Clin Gastroenterol. 2008;42:522–6. - Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF
treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD
cohort study. Inflamm Bowel Dis. 2017;23:1174–81. - Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, et al. Treatment with
infliximab is associated with increased markers of bone formation in patients with Crohn’s
disease. J Clin Gastroenterol. 2006;40:55–63. - Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, et al. Rapid improve-
ment of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol
Ther. 2004;20:607–14. - Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, et al. Effect
of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn’s
disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851–7. - Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with
improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005;100:2031–5. - Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab ther-
apy in Crohn’s disease patients. Can J Gastroenterol. 2007;21:637–42. - Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha
therapy on spinal bone mineral density in patients with Crohn’s disease. Ann N Y Acad Sci.
2006;1068:543–56.
4 Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory